Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy

We retrospective analyzed triple negative breast cancer (TNBC) patients who received either taxane-based or anthracycline-based neoadjuvant chemotherapy, evaluated whether pathological complete response (pCR) is a surrogate endpoint for relapse free survival (RFS) in TNBC and explored which subgroup...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, JunJie, Chen, Sheng, Chen, CanMing, Di, GenHong, Liu, GuangYu, Wu, Jiong, Shao, ZhiMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392337/
https://www.ncbi.nlm.nih.gov/pubmed/27191991
http://dx.doi.org/10.18632/oncotarget.9369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392337/
https://www.ncbi.nlm.nih.gov/pubmed/27191991
http://dx.doi.org/10.18632/oncotarget.9369

Ejemplares similares